Study summary

Sacituzumab govitecan beat chemo for people who cannot have immunotherapy

ASCENT-03 trial (sacituzumab govitecan) · 558 people, phase 3 · Published October 2025, New England Journal of Medicine

9.7months without progression, vs 6.9 with chemotherapy

What was tested

Sacituzumab govitecan against chemotherapy as first treatment for advanced TNBC in people who could not receive PD-1 or PD-L1 immunotherapy.

What they found

What it means

Moves sacituzumab govitecan from later treatment to first treatment for many patients.

N Engl J Med, via PubMed ↗ Trial record NCT05382299 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.